The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening

Dhruva, Sanket S.; Smith-Bindman, Rebecca; Redberg, Rita F.

doi:10.1001/jamainternmed.2023.3610

Search citation statements

Order By: Relevance

Paper Sections

Select...

Liquid Biopsies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Authors from the University of California, San Francisco, wrote in an editorial that randomised clinical trials would be essential before multicancer early detection tests (MCED, also called liquid biopsies) for asymptomatic individuals were approved by the Food and Drug Administration, accepted by insurance companies, and adopted in clinical practice 5…”

Section: Liquid Biopsiesmentioning

confidence: 99%

Cancer screening: Study challenges whether six common tests save lives

Tanne

2023

BMJ

View full text Add to dashboard Cite

Section: Liquid Biopsiesmentioning

confidence: 99%

Cancer screening: Study challenges whether six common tests save lives

Tanne

2023

BMJ

View full text Add to dashboard Cite

Addressing positive multi-cancer early detection tests in head and neck Surgery: Experience with head and neck work up for high-risk referrals

Fearington,

Zhao,

Romero-Brufau

et al. 2024

Oral Oncology

View full text Add to dashboard Cite

Randomized trials of multicancer screening tests: augmenting their ability to identify a genuine mortality benefit

Weiss

2024

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

Randomized trials of the efficacy of multi-cancer early detection, by means of measurement of cell-free DNA and/or protein biomarkers in peripheral blood specimens, will attempt to document a difference in cancer mortality between persons assigned to intervention and control arms. Their ability to do so is limited by the relatively low rate of death from individual forms of cancer, the relatively low sensitivity of the tests currently being used, and the use of other cancer screening modalities among trial participants. However, if those same blood specimens also could be obtained from control arm participants in a given trial and then tested for the same markers, with results not known (or not made available) until the conclusion of follow-up for cancer mortality, it would be possible to compare mortality from given forms of cancer between test-positive individuals whose results were known and not known during the course of the trial. Such an analysis addresses the impact of a stimulus to offer targeted diagnostic testing, potentially leading to early treatment, against cancer mortality. Among persons who screen as positive, it should provide a relatively more sensitive means of gauging a possible mortality benefit resulting from multi-cancer screening.

show abstract

The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening

Cited by 3 publications

References 20 publications

Cancer screening: Study challenges whether six common tests save lives

Cancer screening: Study challenges whether six common tests save lives

Addressing positive multi-cancer early detection tests in head and neck Surgery: Experience with head and neck work up for high-risk referrals

Randomized trials of multicancer screening tests: augmenting their ability to identify a genuine mortality benefit

Contact Info

Product

Resources

About